A switch in therapy to a reverse transcriptase inhibitor sparing combination of lopinavir/ritonavir and raltegravir in virologically suppressed HIV-infected patients: A pilot randomized trial to assess efficacy and safety profile: The KITE study

AIDS Research and Human Retroviruses

Volumn 28, Issue 10, 2012, Pages 1196-1206

  Ofotokun, Ighovwerha ^a,b   Sheth, Anandi N ^a   Sanford, Sara E ^a   Easley, Kirk A ^b   Shenvi, Neeta ^b   White, Kelly ^c   Eaton, Molly E ^a,b   Del Rio, Carlos ^a,b,d   Lennox, Jeffrey L ^a,b  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

^c ABBOTT LABORATORIES   (United States)

^d EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RALTEGRAVIR; VIRUS RNA;

ABDOMINAL PAIN; ADULT; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; COUGHING; DIARRHEA; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FLATULENCE; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTRIGLYCERIDEMIA; INSOMNIA; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MYALGIA; NAUSEA; OPEN STUDY; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; TREATMENT OUTCOME;

ACQUIRED IMMUNODEFICIENCY SYNDROME; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; LIPIDS; LOPINAVIR; MALE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES; PYRROLIDINONES; RITONAVIR; RNA, VIRAL; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84864567279     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2011.0336     Document Type: Article

References (39)

1. U.S. Department of Health and Human Services Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. http://www.aidsinfo.nih.gov/contentfiles/adultandadolescentgl.pdf. Accessed on May 20, 2011.
2. WHO: Antiretroviral therapy for HIV infection in adults and adolescents: Recommendations for a public health approach: 2010 revision. http://whqlibdoc.who.int/publications/2010/9789241599764-eng.pdf. Accessed on May 20, 2011.
3. UK Guidelines for the management of sexual and reproductive health of people living with HIV infection. http://www.bhiva.org/cms1222226.asp. Accessed on May 20, 2011.
4. 3 on long-term combination antiretroviral therapy reach same mortality rates as the general population. J Acquir Immune Defic Syndr 2007;46(1):72-77.
5. Bhaskaran K, Hamouda O, Sannes M, et al.: Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008;300(1):51-59.
6. Lohse N, Hansen AB, Pedersen G, et al.: Survival of persons with and without HIV infection in Denmark, 1995-2005. Ann Intern Med 2007;146(2):87-95.
7. Lima VD, Hogg RS, Harrigan PR, et al.: Continued improvement in survival among HIV-infected individuals with newer forms of highly active antiretroviral therapy. AIDS 2007;21(6):685-692.
8. Currier JS and Havlir DV: Complications of HIV disease and antiretroviral therapy. Top HIV Med 2009;17(2):57-67.
9. Goethals O, Vos A, Van Ginderen M, et al.: Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles. Virology 2010;402(2):338-346.
10. Miller V, de Bethune MP, Kober A, et al.: Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998;42(12):3123-3129.
11. Montaner JS, Cote HC, Harris M, et al.: Nucleoside-related mitochondrial toxicity among HIV-infected patients receiving antiretroviral therapy: Insights from the evaluation of venous lactic acid and peripheral blood mitochondrial DNA. Clin Infect Dis 2004;38(Suppl 20):S73-79.
12. Cooper RD, Wiebe N, Smith N, Keiser P, Naicker S, and Tonelli M: Systematic review and meta-analysis: Renal safety of tenofovir disoproxil fumarate in HIV-infected patients. Clin Infect Dis 2010;51(5):496-505.
13. Hetherington S, McGuirk S, Powell G, et al.: Hypersensitivity reactions during therapy with the nucleoside reverse tran-scriptase inhibitor abacavir. Clin Ther 2001;23(10):1603-1614.
14. Negredo E, Molto J, Burger D, et al.: Unexpected CD4 cell count decline in patients receiving didanosine and tenofovir-based regimens despite undetectable viral load. AIDS 2004;18(3):459-463.
15. Kozal MJ, Lupo S, DeJesus E, et al.: The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an In-vestigational NRTI-and RTV-Sparing Regimen of Ataza-navir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Näive HIV-Infected Subjects. Abstract and Program of the 18th International AIDS Conference (IAC) July 18-23 2010, Vienna, Austria. Abstract THLBB204.
16. Lennox JL, DeJesus E, Lazzarin A, et al.: Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: A multicentre, double-blind randomised controlled trial. Lancet 2009;374(9692):796-806.
17. Markowitz M, Nguyen BY, Gotuzzo E, et al.: Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor ral-tegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: Results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007;46(2):125-133.
18. Steigbigel RT, Cooper DA, Teppler H, et al.: Long-term efficacy and safety of raltegravir combined with optimized background therapy in treatment-experienced patients with drug-resistant HIV infection: Week 96 results of the BENCHMRK 1 and 2 Phase III trials. Clin Infect Dis 2010; 50(4):605-612.
19. Hicks C and Gulick RM: Raltegravir: The first HIV type 1 integrase inhibitor. Clin Infect Dis 2009;48(7):931-939.
20. Cooper DA, Steigbigel RT, Gatell JM, et al.: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-365.
21. Reuman EC, Bachmann MH, Varghese V, Fessel WJ, and Shafer RW: Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother 2010;54(2):934-936.
22. Marcelin AG, Ceccherini-Silberstein F, Perno CF, and Calvez V: Resistance to novel drug classes. Curr Opin HIV AIDS 2009;4(6):531-537.
23. Murphy RL, Brun S, Hicks C, et al.: ABT-378/ritonavir plus stavudine and lamivudine for the treatment of antiretroviral-naive adults with HIV-1 infection: 48-week results. AIDS 2001;15(1):F1-9.
24. Cvetkovic RS and Goa KL: Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003; 63(8):769-802.
25. Kempf DJ, King MS, Bernstein B, et al.: Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. J Infect Dis 2004;189(1):51-60.
26. Naeger LK and Struble KA: Effect of baseline protease genotype and phenotype on HIV response to atazanavir/ri-tonavir in treatment-experienced patients. AIDS 2006;20(6): 847-853.
27. Kassahun K, McIntosh I, Cui D, et al.: Metabolism and disposition in humans of raltegravir (MK-0518), an anti-AIDS drug targeting the human immunodeficiency virus 1 in-tegrase enzyme. Drug Metab Dispos 2007;35(9):1657-1663.
28. Iwamoto M, Kassahun K, Troyer MD, et al.: Lack of a pharmacokinetic effect of raltegravir on midazolam: In vitro/in vivo correlation. J Clin Pharmacol 2008;48(2):209-214.
29. Burger DM: Raltegravir: A review of its pharmacokinetics, pharmacology and clinical studies. Expert Opin Drug Metab Toxicol 2010;6(9):1151-1160.
30. Lopinavir/ritonavir (kaletra) package insert: http://www.rxabbott.com/ pdf/kaletratabpi.pdf. Accessed on May 20, 2011.
31. Reynolds NR, Sun J, Nagaraja HN, Gifford AL, Wu AW, and Chesney MA: Optimizing measurement of self-reported adherence with the ACTG Adherence Questionnaire: A cross-protocol analysis. J Acquir Immune Defic Syndr 2007; 46(4):402-409.
32. Eron JJ, Young B, Cooper DA, et al.: Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): Two multicentre, double-blind, randomised controlled trials. Lancet 2010; 375(9712):396-407.
33. Martinez E, Larrousse M, Llibre JM, et al.: Substitution of raltegravir for ritonavir-boosted protease inhibitors in HIV-infected patients: The SPIRAL study. AIDS 2010;24(11): 1697-1707.
34. Taiwo B, Zheng L, Gallien S, et al.: Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262). AIDS 2011;25(17):2113-2122.
35. Taiwo B ZS, Gallien S, Matining R, Kuritzkes D, Wilson C, Berzins B, Acosta E, Kim P, Eron J, and the ACTG A5262 Team: Results from a Single Arm Study of Darunavir/Ri-tonavir Plus Raltegravirin Treatment-Naïve HIV-1-Infected Patients (ACTG A5262). Program and Abstracts of the 18th Conference on Retroviruses and Opportunistic Infections, February 27-March 2, 2011 at Hynes Convention Center in Boston, MA. Abstract #551.
36. Reynes J LA, Pulido F, Soto-Malave R, Gathe J, Tian M, Fredrick L, Correll T, Podsadecki T, and Nilius A: Lopina-vir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naive HIV-1 infected subjects: PROGRESS 48 week results. Programs and Abstracts of the XVIII International AIDS Conference, Vienna, July 18-23, 2010. Abstract MOAB0101.
37. Murrir CA, De Luca A, Di Giambenedetto S, Marasca G, De Matteis G, Mazzocato V, Fabbiani M, Pinnetti C, and Tam-burrini E: Asymmetry of the regimen is correlated to self-reported suboptimal adherence: results from AdUCSC, a cohort study on adherence in Italy. J Acquir Immune Defic Syndr 2010;55:411-412.
38. Garrido CRN, Zahonero N, de la O López M, Soriano V, de Mendoza C, and Benito JM: Impact of Raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia. J Int AIDS Soc 2010; 13(Suppl 3):O12.
39. Gandhi RT, Zheng L, Bosch RJ, et al.: The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: A randomized controlled trial. PLoS Med 2010;7(8).